期刊
CURRENT OPINION IN VIROLOGY
卷 13, 期 -, 页码 17-24出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2015.03.008
关键词
-
类别
资金
- Oryx GmbH
- German Research Council (DFG) [RA 1891/2-1]
The H-1 parvovirus (H-1PV) exerts oncosuppressive action that has two components: oncotoxicty and imnnunostimulation. While many human tumor cells, including conventional drug-resistant ones, can be killed by H-1PV, some fail to support progeny virus production, necessary for infection propagation in neoplastic tissues. This limitation can be overcome through forced selection of H-1PV variants capable of enhanced multiplication and spreading in human tumor cells. In the context of further developing H-1PV for use in cancer therapy, arming it with immunostimulatory CpG motifs under conditions preserving replication and oncolysis enhances its action as an anticancer vaccine adjuvant. A first clinical study of H-1PV treatment in glioma patients has yielded evidence of intratumoral synthesis of the viral oncotoxic protein NS1 and immune cell infiltration.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据